Gujarat Terce Laboratories Ltd (524314)

Gujarat Terce Laboratories has entered into an agreement to purchase corporate office premises named 'Swati18' in Ahmedabad for ₹3.23 crore. The property spans 2,012.20 sq. ft. and is being acquired from Swatisandhya Procon LLP. Relative to the company's financials, the ₹3.23 crore acquisition represents ~32% of its net worth (₹10 crore) and ~10% of TTM revenue (₹32 crore). The transaction is not a related-party transaction and is entered into at arm's length.

• Purchase consideration of ₹3.23 crores (exclusive of taxes and stamp duty)
• Acquisition of 2,012.20 sq. ft. of corporate office premises at 'Swati18', Ahmedabad
• Counterparty is Swatisandhya Procon LLP with zero promoter relationship
• Acquisition value constitutes ~32% of current net worth (₹10 crore)

Gujarat Terce Laboratories Ltd announced the approval of its unaudited standalone financial results for Q2 and H1 ended 30 September 2026. The board meeting commenced at 3:00 p.m. and concluded at 4:35 p.m. on 5 November 2026. Statutory auditors Shah Doshi Patel & Associates LLP issued an unmodified limited review report on the results. Specific revenue and profit figures were omitted from the text extract of the covering letter.

• Board approved unaudited standalone results for the quarter and half year ended 30 September 2026
• Statutory auditor Shah Doshi Patel & Associates LLP issued an unmodified review report
• Board meeting held on 5 November 2026 lasted 1 hour 35 minutes (3:00 p.m. to 4:35 p.m.)

Gujarat Terce Laboratories shareholders approved the re-appointment of Mr. Aalap Prajapati as Managing Director & CEO at the 41st AGM held on August 21, 2026. His re-appointment is effective for a 3-year term spanning October 28, 2026 to October 27, 2029. Mr. Prajapati brings over 15 years of pharmaceutical industry experience and is the son of Whole-Time Director Natwarbhai Prajapati. The decision ensures continuity in top leadership for the micro-cap pharma company (market cap ~₹27 Cr).

• Re-appointment of Mr. Aalap Prajapati as MD & CEO approved at the 41st AGM on August 21, 2026
• New tenure spans 3 years, effective from October 28, 2026 to October 27, 2029
• Mr. Prajapati possesses over 15 years of industry experience across business strategy and operations
• Directorship is liable to retire by rotation

Gujarat Terce Laboratories Ltd has issued a corrigendum clarifying the re-appointment tenure of Mr. Aalap Prajapati as Managing Director & CEO. The earlier disclosure dated 29 May 2026 erroneously cited a 5-year tenure up to 27 October 2031, whereas the correct tenure is 3 years, running from 28 October 2026 to 27 October 2029. The re-appointment for the 3-year term was approved by shareholders at the 41st Annual General Meeting held on 21 August 2026.

• Re-appointment tenure of MD & CEO Mr. Aalap Prajapati corrected from 5 years to 3 years
• Term effective from 28 October 2026 to 27 October 2029
• Shareholder approval obtained at the 41st AGM held on 21 August 2026
• Mr. Aalap Prajapati possesses over 15 years of experience in the pharmaceutical sector

Gujarat Terce Laboratories has approved its unaudited standalone financial results for the quarter ended June 30, 2026. The company, a micro-cap pharmaceutical player with a ₹31 Cr market capitalization, is coming off a profitable FY26 (PAT ₹2.2 Cr) following a loss-making FY25. The statutory auditors, Shah Doshi Patel & Associates LLP, provided an unmodified limited review report, indicating no major accounting discrepancies were found during the review.

• Board approved unaudited standalone financial results for the quarter ended June 30, 2026
• Statutory auditors issued an unmodified Limited Review Report for the Q1 period
• The board meeting was conducted within a 90-minute window (3:00 PM to 4:30 PM)
• Company maintains a low Debt-to-Equity ratio of 0.13 as per latest annual data

Gujarat Terce Laboratories has scheduled a board meeting for August 7, 2026, to approve its unaudited standalone financial results for the quarter ended June 30, 2026. The company currently has a market capitalization of Rs 27 Cr and reported a TTM revenue of Rs 47 Cr with a PAT of Rs 2 Cr. Investors will be looking for performance improvements compared to the same quarter last year (June 2025), which saw a net loss of Rs 0.04 Cr. The trading window for insiders remains closed until August 9, 2026.

• Board meeting scheduled for August 7, 2026, to approve Q1 results.
• Financial results pertain to the first quarter ended June 30, 2026.
• Trading window closed for 40 days from July 1, 2026, to August 9, 2026.
• Company reported a TTM revenue of Rs 47 Cr as of the latest financial context.
• Previous quarter (March 2026) saw a marginal net profit of Rs 0.1 Cr.

Gujarat Terce Laboratories reported a 5% decline in FY26 revenue to ₹47.47 crore, attributed to a strategic exit from low-margin B2B manufacturing and regulatory headwinds affecting the Acolate Plus brand. However, the company achieved a net profit of ₹2.20 crore and reduced long-term debt to near zero, while debtor days improved to under 37. Management is focusing on its branded portfolio, specifically targeting ₹10 crore for the TYNOL brand in FY27, up from ₹5.75 crore in FY26. Promoter skin-in-the-game increased as the MD converted warrants at a premium, raising his stake to 40.03%.

• FY26 Revenue stood at ₹47.47 crore, a 5% decline from the previous year due to B2B scale-down.
• Net profit returned to ₹2.20 crore with an EBITDA of ₹3.63 crore, representing a 7.66% margin.
• Flagship brand TYNOL achieved ₹5.75 crore in FY26, with a 19.3% 5-year CAGR and a ₹10 crore target for FY27.
• Promoter holding increased by 3% to 40.03% through warrant conversion at a premium of ₹37.70.
• Operational efficiency improved with debtor days falling below 37 days and long-term debt reduced to near zero.